Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Brunswick Adds New Reporting Segment Beginning 1Q23

Brunswick Corporation (NYSE:BC) has updated its reportable segments from three segments to four – Propulsion, Engine Parts & Accessories, Navico Group…
byAkanksha Bakshi
April 10, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0
  • Brunswick Corporation (NYSE:BC) has updated its reportable segments from three segments to four – Propulsion, Engine Parts & Accessories, Navico Group and Boat, effective the first quarter of 2023.
  • Brunswick split its Parts & Accessories reportable segment into Engine Parts & Accessories and Navico Group.
  • The Navico Group segment represents the organizational integration between the legacy Advanced Systems Group business with two key acquisitions, Navico and RELiON.
  • The Engine Parts & Accessories segment comprises Mercury Marine and Quicksilver engine parts and consumables.
  • “With the continued integration of the Navico business and the significant restructuring actions already completed in early 2023, we feel the decision to change our reportable segments will give our stakeholders better visibility into our Company and more closely align with our internal operating structure,” commented Dave Foulkes, Brunswick Corporation CEO.
  • The company is expected to release its 1Q23 financial results on Thursday, April 27, 2023, before the market opens.
  • Price Action: BC shares closed lower by 1.65% at $76.21 on Thursday.
 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Why Palisade Bio Stock Is Soaring Today

By Erica Kollmann
April 16, 11:47 AM
Palisade Bio shares are trading higher Tuesday after the company announced the completion of its analysis evaluating ex-vivo bioactivation of PALI-2108. Palisade Bio said the findings demonstrated PALI-2108 exhibited efficient ex-vivo conversion into its active PDE4 inhibitor form in stool samples from both normal healthy volunteers and patients with ulcerative colitis (UC). The assessment showed PALI-2108 was converted into its active PDE4 inhibitor form at a mean rate of 90.1% with conversion steadily increasing over time.

PALI